

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the Application:

Listing of Claims:

1. (Currently Amended) An *in vitro* method for producing dendritic cells from pluripotential cells, comprising contacting the pluripotential cells with a factor for a time sufficient for the pluripotential cells to mature and express a characteristic of dendritic cells, wherein the characteristic is selected from the group consisting of increased CD83 expression, increased CD86 expression, decreased CD115 expression, and decreased CD32 expression relative to the pluripotential cells.
2. (Original) The method of claim 1, wherein the pluripotential cells are CD14 positive mononuclear pluripotential cells.
3. (Original) The method of claim 1, wherein the pluripotential cells are peripheral blood mononuclear cells.
4. (Original) The method of claim 1, wherein the pluripotential cells are monocytes.
5. (Original) The method of claim 1, wherein the factor comprises GM-CSF.
6. (Original) The method of claim 5, wherein the factor further comprises a cytokine selected from the group consisting of IL-4; IL-13; IL-4 and IL-1 β ; IL-13 and IL-1 β ; IL-4 and TNF- α ; IL-13 and TNF- α ; IL-4, IL-1 β , and TNF- α ; IL-13, IL-1 β , and TNF- α ; IL-4 and IL-12; IL-13 and IL-12; IL-4 and stem cell factor, IL-13 and stem cell factor; IL-4 and IL-15; and IL-13 and IL-15.
- 7-9. (Cancelled)
10. (Previously Added) The method of claim 6, wherein the GM-CSF is present at a concentration of between about 200 U/ml to about 2000 U/ml.
11. (Previously Added) The method of claim 1, wherein the dendritic cells express high levels of MHC class molecules.
12. (Previously Added) The method of claim 1, wherein the dendritic cells have the capacity to stimulating resting T cells.